

**ABSTRACT**

Specific antagonists for prokaryotic or eukaryotic integral membrane proteins are provided. The antagonists are peptides having the amino acid sequence of a transmembrane domain of the integral membrane proteins or of a portion or analogue thereof. Methods are provided for preventing or treating disorders characterised by disordered function of an integral membrane protein by administration of a specific peptide antagonist of the integral membrane protein.

---